Measurement of circulating GDF-15 provides incremental improvement in mortality risk prediction in addition to traditional risk factors as well as cTns and BNP in healthy individuals as well in patients with a spectrum of CVD including AMI and HF. Higher circulating GDF-15 is associated with incident renal outcomes and improves risk prediction of incident CKD. This evidence concerns the gene GDF15 and chronic kidney disease.